A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

Summary

This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).

Timeline

Start

2020-06-18

Primary completion

2024-06-11

Completion

2024-06-11

Publications

• Matsumori Y, Nagy K, Takahashi A, Tanaka S, Takeshima T, Forero G, Bao J, Guo H, Ahmadyar G, de Abreu Ferreira R, Yamamoto T. Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study. Neurol Ther. 2026 Jun;15(3):1137-1154. doi: 10.1007/s40120-026-00905-3. Epub 2026 Mar 11.

Drugs

Indications